Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

Launched by NEW YORK STATE PSYCHIATRIC INSTITUTE · Apr 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called sublingual buprenorphine for treating opioid use disorder (OUD). The trial will compare two ways of receiving treatment: one group will have in-person visits with healthcare providers, while another group will receive the same treatment through telehealth sessions, which means they can connect with their doctors online instead of going to a clinic. The goal is to see if telehealth can be just as effective as in-person care for helping people who are trying to overcome their addiction to opioids.

To participate in this study, individuals must be between the ages of 65 and 74 and voluntarily seeking treatment for opioid use disorder. They need to meet certain criteria, like being able to understand the study and follow its rules. However, people with other serious substance use issues, certain mental health conditions, or specific medical problems may not be eligible. If you join the study, you can expect to receive either the in-person or telehealth treatment, along with support from healthcare professionals throughout the process. This trial is not yet recruiting participants, but it aims to provide valuable insights into how we can effectively treat opioid use disorder.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • meet DSM-5 criteria for OUD
• • Voluntarily seeking buprenorphine treatment for OUD
• • Able to provide informed consent and comply with study procedures
• Exclusion Criteria:
• • Meeting DSM-5 criteria for substance use disorder other than opioid as the primary diagnosis that would compromise safety of participation in the trial as determined by the study physician, such as an alcohol or sedative hypnotic use disorder that requires detoxification
• • Having a comorbid psychiatric diagnosis that might interfere with participation or make participation hazardous, such as a psychotic disorder including schizophrenia or schizoaffective disorder
• • Concurrent methadone, buprenorphine, or vivitrol maintenance treatment
• • Known history of allergy, intolerance, or hypersensitivity to candidate medication (buprenorphine)
• • Pregnancy, lactation, or failure to use adequate contraceptive methods in female patients
• • Unstable medical conditions, such as severe hepatic, renal, or cardiovascular disease, which might make participation
• • Current or recent history history of significant violent or suicidal behavior or risk for suicide or homicide
• • Legally mandated to substance use disorder treatment.